Document Detail


Safety profile of trabectedin in combination with liposomal pegylated doxorrubicin in relapsed ovarian carcinoma: considerations for optimal management.
MedLine Citation:
PMID:  21540668     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The toxicity profile of trabectedin in the OVA-301 trial, that combined trabectedin with pegylated liposomal doxorubicin for the treatment of patients with ovarian cancer, has shown to be predictable and manageable. No unexpected toxicities were found, with neutropenia and transient increase in transaminases as the most common adverse events reported. The elevation in transaminases appeared early and generally decreased in incidence and intensity over subsequent cycles, with no major clinical consequences. A similar safety profile was seen in the analysis of the older patients in the trial. There were no detrimental effects in quality of life with the combination. Moreover, the Global Health Status score was better for the combination arm in those patients with a PFI of 6 to 12 months that were in response after 5 cycles. Trabectedin with pegylated liposomal doxorubicin is not associated with cumulative end-organ toxicities (renal, cardiac, or neurological toxicities). The toxicity profile is different from other second-line strategies without the presence of inconvenient side effects, such as alopecia, hypersensitivity reactions, hand-foot syndrome, or mucositis.
Authors:
Antonio González Martín
Related Documents :
2082958 - A pilot study of recombinant interferon beta (ifn-beta ser) in patients with recurrent ...
11740478 - Use of intralesional interferon-alpha for the treatment of recalcitrant oral warts in p...
15657158 - Antiviral therapy for cirrhotic hepatitis c: association with reduced hepatocellular ca...
21248448 - Eight-year experience in esophageal cancer surgery.
14632848 - Preoperative serum acid phosphatase and alkaline phosphatase are not predictors of path...
1697498 - Prostatic specific antigen and the prediction of prognosis in metastatic prostatic cancer.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society     Volume:  21 Suppl 1     ISSN:  1525-1438     ISO Abbreviation:  Int. J. Gynecol. Cancer     Publication Date:  2011 May 
Date Detail:
Created Date:  2011-05-04     Completed Date:  2011-07-08     Revised Date:  2012-06-08    
Medline Journal Info:
Nlm Unique ID:  9111626     Medline TA:  Int J Gynecol Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  S6-8     Citation Subset:  IM    
Affiliation:
Medical Oncology Department, Cancer Center M.D. Anderson International, Madrid, Spain. agonzalezm@mdanderson.es
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibiotics, Antineoplastic / administration & dosage
Antineoplastic Agents, Alkylating / administration & dosage,  adverse effects*
Antineoplastic Combined Chemotherapy Protocols
Carcinoma / drug therapy*
Dioxoles / administration & dosage,  adverse effects*
Doxorubicin / administration & dosage
Female
Humans
Liposomes
Ovarian Neoplasms / drug therapy*
Patient Compliance
Quality of Life
Recurrence
Tetrahydroisoquinolines / administration & dosage,  adverse effects*
Chemical
Reg. No./Substance:
0/Antibiotics, Antineoplastic; 0/Antineoplastic Agents, Alkylating; 0/Dioxoles; 0/Liposomes; 0/Tetrahydroisoquinolines; 114899-77-3/trabectedin; 23214-92-8/Doxorubicin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  An increasing role for trabectedin in gynecological cancers: efficacy in uterine sarcomas.
Next Document:  Benefits of enhancing the platinum-free interval in the treatment of relapsed ovarian cancer: more t...